Approach
Approach
We provide capital as well as strategic support.
We provide capital as well as strategic support.
Value Proposition
Value Proposition
Pre-built Deal Flow
Strong Deal Pipeline, Pro-rata Rights.
Higher ROI
Shorter Term Exits (4-5 yrs, not 10-12).
Respected Brand
Hands-on GP and Advisors. Value Added Investors.
Relevant Industries
in ESG, with High VC/ M&A activities.
De-risking Attitude
Known verticals, Strategic Exits.
Pre-built Deal Flow
Strong Deal Pipeline, Pro-rata Rights.
Higher ROI
Shorter Term Exits (4-5 yrs, not 10-12).
Respected Brand
Hands-on GP and Advisors. Value Added Investors.
Relevant Industries
in ESG, with High VC/ M&A activities.
De-risking Attitude
Known verticals, Strategic Exits.
Strong Deal Pipeline, Pro-rata Rights.
Higher ROI
Shorter Term Exits (4-5 yrs, not 10-12).
Respected Brand
Hands-on GP and Advisors. Value Added Investors.
Relevant Industries
in ESG, with High VC/ M&A activities.
De-risking Attitude
Known verticals, Strategic Exits.
Verticals
Verticals
Approach
Approach
We provide capital and strategic support for fast growing companies
We provide capital and strategic support for fast growing companies
Value Proposition
Value Proposition
Pre-built Deal Flow
Strong Deal Pipeline,
Pro-rata Rights.
Higher ROI
Shorter Term Exits
(3-5 yrs, not 10-12).
Respected Brand
Hands-on GP and Advisors.
Value Added Investors.
Relevant Industries
in ESG, with High
VC/M&A activities.
De-risking Attitude
Known verticals,
Strategic Exits.
Pre-built Deal Flow
Strong Deal Pipeline,
Pro-rata Rights.
Higher ROI
Shorter Term Exits
(3-5 yrs, not 10-12).
Respected Brand
Hands-on GP and Advisors.
Value Added Investors.
Relevant Industries
in ESG, with High
VC/M&A activities.
De-risking Attitude
Known verticals,
Strategic Exits.
Strong Deal Pipeline,
Pro-rata Rights.
Higher ROI
Shorter Term Exits
(3-5 yrs, not 10-12).
Respected Brand
Hands-on GP and Advisors.
Value Added Investors.
Relevant Industries
in ESG, with High
VC/M&A activities.
De-risking Attitude
Known verticals,
Strategic Exits.
Verticals
Verticals
Team
Team
We are operators with a shared vision of providing capital and strategic support, reducing risk, and increasing profitability to companies that are good for investors, the planet, people, and the economy.
Our diverse expertise, connections, and points of view are synergistic and provide unparalleled value to our portfolio companies.
We are operators with a shared vision of providing capital and strategic support, reducing risk, and increasing profitability to companies that are good for investors, the planet, people, and the economy.
Our diverse expertise, connections, and points of view are synergistic and provide unparalleled value to our portfolio companies.
Our diverse expertise, connections, and points of view are synergistic and provide unparalleled value to our portfolio companies.
Team
Team
We are operators with a shared vision of providing capital and strategic support, reducing risk, and increasing profitability to companies that are good for investors, the planet, the people, and the economy.
Our diverse expertise, connections, and points of view are synergistic and provide unparalleled value to our portfolio companies.
We are operators with a shared vision of providing capital and strategic support, reducing risk, and increasing profitability to companies that are good for investors, the planet, the people, and the economy.
Our diverse expertise, connections, and points of view are synergistic and provide unparalleled value to our portfolio companies.
Our diverse expertise, connections, and points of view are synergistic and provide unparalleled value to our portfolio companies.
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio News
Portfolio News
In 2024, Skycatch collaborated with Microsoft Azure, NVIDIA Omniverse, and Pamapersada Nusantara, Indonesia’s largest mine site operator, on creating a digital twin of their 19 nationwide projects. Using Skycatch ARAS, the joint solution optimizes haul planning, cutting fleet maintenance costs by 12%, and enhances safety by reducing 12,000 pit interactions per site annually. These improvements significantly boost production yields.
In partnership with Kav Medida, Skycatch also developed SCAN1, a groundbreaking SLAM LiDAR system for the construction and infrastructure sectors. Still in prototype, SCAN1 combines RTK loop closure and LiDAR to capture seamless indoor-outdoor 3D point clouds, as demonstrated with a water tower and pumping station. SCAN1’s transformative potential continues to grow as its capabilities are refined.
Skycatch was also featured in a presentation by Caterpillar as part of their Cat Precision Mining, which leverages data from Skycatch to help operations more rapidly and precisely adjust their planning activities based on measured orebody variations that are present.
Links:
In partnership with Kav Medida, Skycatch also developed SCAN1, a groundbreaking SLAM LiDAR system for the construction and infrastructure sectors. Still in prototype, SCAN1 combines RTK loop closure and LiDAR to capture seamless indoor-outdoor 3D point clouds, as demonstrated with a water tower and pumping station. SCAN1’s transformative potential continues to grow as its capabilities are refined.
Skycatch was also featured in a presentation by Caterpillar as part of their Cat Precision Mining, which leverages data from Skycatch to help operations more rapidly and precisely adjust their planning activities based on measured orebody variations that are present.
Links:
In 2024, Avenda Health made significant strides in advancing prostate cancer care with its AI-powered platform, Unfold AI. This technology integrates patient-specific data from imaging, biopsies, and pathology to create detailed 3D cancer estimation maps.
Platform Implementation and Trials
The platform was commercially implemented for the first time in March 2024 at a leading U.S. research hospital. Physicians, including Dr. Wayne Brisbane, utilized the technology to visualize cancer extent and enhance treatment outcomes. Clinical studies further validated its impact, with research published in the Journal of Urology demonstrating that Unfold AI significantly reduces the risk of underestimating cancer extent. The study showed a 45-fold improvement in cancer size prediction accuracy compared to traditional imaging and blood tests.
Collaboration with EDAP TMS
In a major technological breakthrough, Avenda Health collaborated with EDAP TMS SA to launch the world’s first AI-assisted Focal One robotic high-intensity focused ultrasound (HIFU) procedures. This integration ensures greater precision in targeting cancerous tissue while sparing healthy tissue, paving the way for safer and more effective treatments.
Milestones
Regulatory and financial milestones also marked the year for Avenda Health. The Centers for Medicare and Medicaid Services (CMS) assigned a national payment rate to Unfold AI, recognizing its transformative role in prostate cancer mapping. Additionally, the American Medical Association introduced a Category III code (0898T) to facilitate reimbursement for using this innovative platform. These developments ensure broader access to the technology and underscore its growing acceptance in the healthcare industry.
Avenda Health’s accomplishments in 2024 reflect its commitment to leveraging artificial intelligence to revolutionize prostate cancer care, improve diagnostic accuracy, and enhance patient outcomes globally.
Links:
Platform Implementation and Trials
The platform was commercially implemented for the first time in March 2024 at a leading U.S. research hospital. Physicians, including Dr. Wayne Brisbane, utilized the technology to visualize cancer extent and enhance treatment outcomes. Clinical studies further validated its impact, with research published in the Journal of Urology demonstrating that Unfold AI significantly reduces the risk of underestimating cancer extent. The study showed a 45-fold improvement in cancer size prediction accuracy compared to traditional imaging and blood tests.
Collaboration with EDAP TMS
In a major technological breakthrough, Avenda Health collaborated with EDAP TMS SA to launch the world’s first AI-assisted Focal One robotic high-intensity focused ultrasound (HIFU) procedures. This integration ensures greater precision in targeting cancerous tissue while sparing healthy tissue, paving the way for safer and more effective treatments.
Milestones
Regulatory and financial milestones also marked the year for Avenda Health. The Centers for Medicare and Medicaid Services (CMS) assigned a national payment rate to Unfold AI, recognizing its transformative role in prostate cancer mapping. Additionally, the American Medical Association introduced a Category III code (0898T) to facilitate reimbursement for using this innovative platform. These developments ensure broader access to the technology and underscore its growing acceptance in the healthcare industry.
Avenda Health’s accomplishments in 2024 reflect its commitment to leveraging artificial intelligence to revolutionize prostate cancer care, improve diagnostic accuracy, and enhance patient outcomes globally.
Links:
In 2024, Nanochon achieved significant milestones in its mission to revolutionize joint health through advanced 3D-printed implants.
Funding and Financial Growth
In May 2024, Nanochon secured $4 million in a Series Seed Prime funding round. This round was led by The University of Virginia Licensing and Ventures Group Seed Fund, with participation from Cultivate (MD), Alumni Venture Group, and Mountain State Capital, among others. The capital is intended to initiate the company's first human clinical trials in the U.S. in 2024 and to deepen research and development efforts.
Strategic Partnerships and Expansion
In November 2024, Nanochon transitioned from JLABS to become a resident at LaunchPort's City Garage/Baltimore Peninsula location. This move aims to enhance the company's manufacturing capabilities and accelerate the development of its innovative cartilage regeneration technology.
Technological Advancements and Thought Leadership
Dr. Ben Holmes, CEO of Nanochon, was featured on the "Biomedical Frontiers" podcast, where he discussed the company's minimally invasive solutions for cartilage regeneration. He highlighted how Nanochon's 3D-printed implants integrate mechanically with the body's natural cartilage structure and promote regeneration in the presence of stem cells.
These developments underscore Nanochon's commitment to advancing joint health through innovative solutions and strategic growth initiatives.
Links:
Funding and Financial Growth
In May 2024, Nanochon secured $4 million in a Series Seed Prime funding round. This round was led by The University of Virginia Licensing and Ventures Group Seed Fund, with participation from Cultivate (MD), Alumni Venture Group, and Mountain State Capital, among others. The capital is intended to initiate the company's first human clinical trials in the U.S. in 2024 and to deepen research and development efforts.
Strategic Partnerships and Expansion
In November 2024, Nanochon transitioned from JLABS to become a resident at LaunchPort's City Garage/Baltimore Peninsula location. This move aims to enhance the company's manufacturing capabilities and accelerate the development of its innovative cartilage regeneration technology.
Technological Advancements and Thought Leadership
Dr. Ben Holmes, CEO of Nanochon, was featured on the "Biomedical Frontiers" podcast, where he discussed the company's minimally invasive solutions for cartilage regeneration. He highlighted how Nanochon's 3D-printed implants integrate mechanically with the body's natural cartilage structure and promote regeneration in the presence of stem cells.
These developments underscore Nanochon's commitment to advancing joint health through innovative solutions and strategic growth initiatives.
Links:
This Texas-based clinical-stage medical device company has made significant strides in 2024, advancing its mission to improve outcomes for hemodialysis patients through its innovative SelfWrap Bioabsorbable Perivascular Wrap.
Funding
The company secured $20 million in Series A financing, led by Norwest Venture Partners, Good Growth Capital, and IAG Capital Partners, alongside a $3.6 million NIH Small Business Innovation Research (SBIR) Phase II grant. These funds have propelled the company into pivotal clinical trials and supported further development of its breakthrough technology.
Launch of Clinical Trial
The FDA’s 2023 approval of VenoStent’s SelfWrap for its Investigational Device Exemption (IDE) study enabled the launch of the SAVE-FistulaS clinical trial in 2024. This first-of-its-kind randomized controlled trial (RCT) in the U.S. is designed to evaluate the effectiveness of SelfWrap in improving arteriovenous fistula (AVF) outcomes for hemodialysis patients.
The SAVE-FistulaS study, enrolling 200 participants across the U.S., compares SelfWrap-treated AVFs to untreated controls. The device works by mimicking the arterial environment in veins, helping them adapt to the high pressure and flow conditions required for successful dialysis access. Over time, the bioabsorbable wrap is resorbed and replaced by venous tissue, addressing the critical failure points in traditional AVF procedures. Primary endpoints include unassisted AVF use for up to six months and the reduction of access-related complications within 30 days.
With substantial funding, FDA authorization, and an ambitious clinical trial underway, VenoStent is poised to revolutionize vascular access for hemodialysis patients. This pivotal year reflects the company’s dedication to addressing a significant unmet clinical need and delivering transformative solutions to the CKD community.
Links:
Funding
The company secured $20 million in Series A financing, led by Norwest Venture Partners, Good Growth Capital, and IAG Capital Partners, alongside a $3.6 million NIH Small Business Innovation Research (SBIR) Phase II grant. These funds have propelled the company into pivotal clinical trials and supported further development of its breakthrough technology.
Launch of Clinical Trial
The FDA’s 2023 approval of VenoStent’s SelfWrap for its Investigational Device Exemption (IDE) study enabled the launch of the SAVE-FistulaS clinical trial in 2024. This first-of-its-kind randomized controlled trial (RCT) in the U.S. is designed to evaluate the effectiveness of SelfWrap in improving arteriovenous fistula (AVF) outcomes for hemodialysis patients.
The SAVE-FistulaS study, enrolling 200 participants across the U.S., compares SelfWrap-treated AVFs to untreated controls. The device works by mimicking the arterial environment in veins, helping them adapt to the high pressure and flow conditions required for successful dialysis access. Over time, the bioabsorbable wrap is resorbed and replaced by venous tissue, addressing the critical failure points in traditional AVF procedures. Primary endpoints include unassisted AVF use for up to six months and the reduction of access-related complications within 30 days.
With substantial funding, FDA authorization, and an ambitious clinical trial underway, VenoStent is poised to revolutionize vascular access for hemodialysis patients. This pivotal year reflects the company’s dedication to addressing a significant unmet clinical need and delivering transformative solutions to the CKD community.
Links:
In 2024, Orbit Fab made significant strides in advancing in-orbit refueling technologies, positioning itself as a key player in sustainable space operations.
RAFTI
Early in the year, the company delivered its first Rapidly Attachable Fuel Transfer Interface (RAFTI) ports to the U.S. Space Force, enabling next-generation satellite refueling capabilities. By August, the U.S. Space Systems Command officially approved the RAFTI interface as the standard for military satellites, further validating its strategic importance.
Partnerships and Company Presence
Orbit Fab also expanded its international footprint, particularly in the UK, where it tripled its workforce and secured £1.3 million in funding from the UK Space Agency. This investment supports the development of advanced high-pressure RAFTI ports for use with pressurized fuels like Xenon. The company forged partnerships with innovators like Magdrive to explore new propulsion and refueling solutions, while also introducing a clear pricing structure for its services, including RAFTI ports priced at $30,000 each and in-orbit refueling services starting at $20 million for 100 kilograms of hydrazine.
These accomplishments underscore Orbit Fab’s leadership in creating sustainable and scalable solutions for the growing space economy, while fostering partnerships and innovations that pave the way for long-term in-orbit operations.
Links:
RAFTI
Early in the year, the company delivered its first Rapidly Attachable Fuel Transfer Interface (RAFTI) ports to the U.S. Space Force, enabling next-generation satellite refueling capabilities. By August, the U.S. Space Systems Command officially approved the RAFTI interface as the standard for military satellites, further validating its strategic importance.
Partnerships and Company Presence
Orbit Fab also expanded its international footprint, particularly in the UK, where it tripled its workforce and secured £1.3 million in funding from the UK Space Agency. This investment supports the development of advanced high-pressure RAFTI ports for use with pressurized fuels like Xenon. The company forged partnerships with innovators like Magdrive to explore new propulsion and refueling solutions, while also introducing a clear pricing structure for its services, including RAFTI ports priced at $30,000 each and in-orbit refueling services starting at $20 million for 100 kilograms of hydrazine.
These accomplishments underscore Orbit Fab’s leadership in creating sustainable and scalable solutions for the growing space economy, while fostering partnerships and innovations that pave the way for long-term in-orbit operations.
Links:
- First Satellite Refueling Ports Shipped
- Completion of Ground Fueling Payload Testing
- Space Systems Command Approves Orbit Fab Refueling Interface For Military Satellites
- Orbit Fab unveils $30k Refueling Ports
- New Partnership For In-Orbit Refueling Development
- Company says 'cosmic petrol station' ready by 2027
- MagDrive Announces MOU with Orbit Fab
- Orbit Fab Sets Price Tag for In-Orbit Refueling Service
- AstroPort and Orbit Fab Partnership for Lunar Exploration Breakthrough
- Orbit Fab Expands European Network To Accelerate In-Orbit Refueling
- UK $2M Investment For In-Orbit Refueling
- UK Space Agency Commits $1M for Satellite Refueling Project
In 2024, ViewMind Inc. achieved significant milestones in advancing neurocognitive health diagnostics.
Bio-Hermes-002 Study
The company joined the Bio-Hermes-002 study in partnership with the Global Alzheimer's Platform Foundation, aiming to enhance Alzheimer's detection through diverse biomarker analysis. This collaboration underscores ViewMind's commitment to improving diagnostic precision across various populations.
Mark Edwards CEO Award
In recognition of his leadership, CEO Mark Edwards was honored as "Healthcare Technology CEO of the Year USA" in the Business Worldwide 2024 CEO Awards. This accolade highlights his pivotal role in steering ViewMind towards innovative solutions in brain health assessments.
North American Technology Innovation Leadership Award
Additionally, ViewMind was acknowledged by Frost & Sullivan with the 2024 North American Technology Innovation Leadership Award for its groundbreaking digital biomarker technology, which stands at the forefront of precision brain health.
These accomplishments reflect ViewMind's dedication to revolutionizing cognitive healthcare through cutting-edge technology and strategic collaborations.
Links
Bio-Hermes-002 Study
The company joined the Bio-Hermes-002 study in partnership with the Global Alzheimer's Platform Foundation, aiming to enhance Alzheimer's detection through diverse biomarker analysis. This collaboration underscores ViewMind's commitment to improving diagnostic precision across various populations.
Mark Edwards CEO Award
In recognition of his leadership, CEO Mark Edwards was honored as "Healthcare Technology CEO of the Year USA" in the Business Worldwide 2024 CEO Awards. This accolade highlights his pivotal role in steering ViewMind towards innovative solutions in brain health assessments.
North American Technology Innovation Leadership Award
Additionally, ViewMind was acknowledged by Frost & Sullivan with the 2024 North American Technology Innovation Leadership Award for its groundbreaking digital biomarker technology, which stands at the forefront of precision brain health.
These accomplishments reflect ViewMind's dedication to revolutionizing cognitive healthcare through cutting-edge technology and strategic collaborations.
Links
- ViewMind Joins Bio-Hermes-002 Landmark Study
- Mark Edwards of ViewMind Wins Business Worldwide Magazine 2024 CEO Award
- ViewMind Applauded by Frost & Sullivan for Revolutionizing Brain Health Assessment and Care with Its Ocular Digital Phenotyping Solution
WavelyDx has made significant strides in 2024, joining the PedsMrkt community—a platform that brings together pediatric innovators to amplify awareness and adoption of cutting-edge healthcare solutions. This partnership strengthens their mission to improve children’s healthcare access while fostering collaborations with like-minded organizations.
Arna Ionescu Stall Recognized
CEO Arna Ionescu Stoll was recognized as a rising leader in healthcare innovation. Under her guidance, WavelyDx continues to expand its impact, including the recent launch of solutions for iPhone users, making them more accessible than ever.
New Additions to Medical Advisory Board
Dr. Michael Mina, MD, PhD: A leading epidemiologist, immunologist, and clinical pathologist, Dr. Mina brings extensive experience from his roles advising U.S. government agencies and spearheading NIH programs like the Home Test to Treat Program. His expertise in digital-first healthcare, honed as Chief Science Officer at eMed, will be invaluable to WavelyDx.
Dr. Sylvia Romm, MD, MPH: A seasoned pediatrician and digital health transformation leader, Dr. Romm has driven innovation in her roles at Atlantic Health System, Cityblock Health, and American Well. Her strategic insight will help propel WavelyDx’s vision for groundbreaking healthcare solutions.
With these developments, WavelyDx is well-positioned for growth as we advance pediatric healthcare innovation and broaden access to vital tools for children and families worldwide.
Links:
LinkedIn Posts
Arna Ionescu Stall Recognized
CEO Arna Ionescu Stoll was recognized as a rising leader in healthcare innovation. Under her guidance, WavelyDx continues to expand its impact, including the recent launch of solutions for iPhone users, making them more accessible than ever.
New Additions to Medical Advisory Board
Dr. Michael Mina, MD, PhD: A leading epidemiologist, immunologist, and clinical pathologist, Dr. Mina brings extensive experience from his roles advising U.S. government agencies and spearheading NIH programs like the Home Test to Treat Program. His expertise in digital-first healthcare, honed as Chief Science Officer at eMed, will be invaluable to WavelyDx.
Dr. Sylvia Romm, MD, MPH: A seasoned pediatrician and digital health transformation leader, Dr. Romm has driven innovation in her roles at Atlantic Health System, Cityblock Health, and American Well. Her strategic insight will help propel WavelyDx’s vision for groundbreaking healthcare solutions.
With these developments, WavelyDx is well-positioned for growth as we advance pediatric healthcare innovation and broaden access to vital tools for children and families worldwide.
Links:
LinkedIn Posts
If you are an entrepreneur, investor, or would like to learn more, connect with us.
Funding Exponential Growth
© 2025 Wealthing VC Fund